Related Experiment Video
Updated: Jan 4, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Focus on FKBP51: A molecular link between stress and metabolic disorders
Alexander S Häusl1, Georgia Balsevich2, Nils C Gassen3
1Research Group Neurobiology of Stress Resilience, Max Planck Institute of Psychiatry, 80804, Munich, Germany.
Background:
Obesity, Type 2 diabetes (T2D) as well as stress-related disorders are rising public health threats and major burdens for modern society. Chronic stress and depression are highly associated with symptoms of the metabolic syndrome, but the molecular link is still not fully understood. Furthermore, therapies tackling these biological disorders are still lacking. The identification of shared molecular targets underlying both pathophysiologies may lead to the development of new treatments. The FK506 binding protein 51 (FKBP51) has recently been identified as a promising therapeutic target for stress-related psychiatric disorders and obesity-related metabolic outcomes.
Scope Of The Review:
The aim of this review is to summarize current evidence of in vitro, preclinical, and human studies on the stress responsive protein FKBP51, focusing on its newly discovered role in metabolism. Also, we highlight the therapeutic potential of FKBP51 as a new treatment target for symptoms of the metabolic syndrome.
Major Conclusions:
We conclude the review by emphasizing missing knowledge gaps that remain and future research opportunities needed to implement FKBP51 as a drug target for stress-related obesity or T2D.
Insights
FKBP51 is a promising target for treating obesity and type 2 diabetes (T2D). Targeting FKBP51 may offer new therapies for metabolic syndrome symptoms linked to chronic stress and depression.
Area of Science:
- Metabolic disorders and psychiatric conditions research
- Molecular mechanisms of stress and metabolism
Background:
- Obesity, Type 2 Diabetes (T2D), and stress-related disorders pose significant public health challenges.
- Chronic stress and depression are linked to metabolic syndrome, but molecular links are unclear.
- FKBP51 is identified as a potential therapeutic target for psychiatric and metabolic conditions.
Purpose of the Study:
- To review evidence on FKBP51's role in metabolism.
- To highlight FKBP51's therapeutic potential for metabolic syndrome.
- To explore FKBP51 as a drug target for stress-related obesity and T2D.
Main Methods:
- In vitro studies
- Preclinical studies
- Human studies
Main Results:
- FKBP51 is implicated in metabolic regulation.
- Evidence supports FKBP51's role in stress-related disorders.
- FKBP51 shows therapeutic promise for metabolic syndrome.
Conclusions:
- FKBP51 is a viable drug target for stress-related obesity and T2D.
- Further research is needed to bridge knowledge gaps.
- Implementing FKBP51 as a therapeutic target requires continued investigation.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Physiological Foundation of Stress
Role of the Sympathetic Nervous System
Adrenaline triggers the...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Regulation of the Unfolded Protein Response
Other Stress Responses in Bacteria
Hypothalamic-Pituitary Axis

